<DOC>
	<DOCNO>NCT02410356</DOCNO>
	<brief_summary>This study assess safety tolerability weekly TV-1106 compare daily rhGH adult GHD previously treat rhGH .</brief_summary>
	<brief_title>Study Assess Safety Tolerability Adults With Growth Hormone-Deficiency ( GHD )</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>male females 18 year age diagnosis adult GHD least 6 month , patient hypopituitarism surgical resection treat stable dose daily rhGH least 3 month prior screen stable , adequate dos replacement hormone ( adrenal , thyroid , estrogen , testosterone , vasopressin ) least 3 month prior screen Other criterion apply , please contact investigator information patient acute chronic condition disease could confound result study put patient undue risk determine investigator Presence contraindication rhGH treatment patient participate another clinical trial new chemical/biological entity within 3 month screen patient know active malignancy ( exclude surgically remove basal cell carcinoma carcinoma situ cervix ) d. patient previously treat pituitary tumor evidence tumor progression past year patient new diagnosis pituitary adenoma intracranial tumor within 12 month screen presence PraderWilli syndrome , Turner 's syndrome , untreated adrenal insufficiency , active acromegaly past 5 year , active Cushing 's syndrome past year . patient type 1 diabetes mellitus oror poorly control type 2 diabetes mellitus indicate glycated hemoglobin ( HbA1c ) â‰¥8 % patient use weight reduce agent appetite suppressant Other criterion apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>